더바이오 10월 2일 주요뉴스
https://www.thebionews.net/edit/webzine.html?idxno=656
●에이프릴 파트너사 에보뮨, 아토피 치료제 후보 2a상 유의미한 치료효과 확인
https://www.thebionews.net/news/articleView.html?idxno=28685
●삼성바이오로직스, 유럽 제약사와 935억원 규모 의약품 위탁생산 계약
https://www.thebionews.net/news/articleView.html?idxno=28722
●‘키트루다·파드셉’, 방광암 수술 전후 치료 새 길…“이상반응 상쇄할 효과”
https://www.thebionews.net/news/articleView.html?idxno=28708
●핀테라퓨틱스, 선양낭성암 대상 ‘PIN-5018’ 가속승인 도전…후속 MGD 확장
https://www.thebionews.net/news/articleView.html?idxno=28706
●티씨노바이오, ULK1 분해 프로탁 ‘TXN12923’ 내년 하반기 임상1상 신청
https://www.thebionews.net/news/articleView.html?idxno=28709
●진양곤 HLB그룹 의장, 개인 명의 이어 ‘개인 법인’ 통해 계열사 지분 확대
https://www.thebionews.net/news/articleView.html?idxno=28707
●美 캔델 “아글라티마진·발라시클로버, ICI 불응 폐암 환자 mOS 24.5개월”
https://www.thebionews.net/news/articleView.html?idxno=28687
●허일섭 GC 회장 “AI·데이터 활용 통한 생산성 혁신해야”
https://www.thebionews.net/news/articleView.html?idxno=28718
●사노피·리제네론, ‘듀피젠트’ 이을 항체 4종 공동 개발…10.8조원 규모 협력
https://www.thebionews.net/news/articleView.html?idxno=28686
●美 레제라, NLRP3 억제제 ‘트라브자노플라스트’ 임상1상서 높은 뇌 노출 확인
https://www.thebionews.net/news/articleView.html?idxno=28680
●리제네론 “트레보그루맙, 2상 위고비 투여 인한 허벅지 근육 손실 약 70%↓”
https://www.thebionews.net/news/articleView.html?idxno=28704
●美컬리넌·日타이호, ‘지팔러티닙’ EGFR 엑손20 폐암 1차치료 FDA 허가신청
https://www.thebionews.net/news/articleView.html?idxno=28705
●동아쏘시오홀딩스, ‘동아제약’ 흡수합병 완료…‘사업지주회사’ 전환
https://www.thebionews.net/news/articleView.html?idxno=28730
●샤페론, ‘니즈테크’ 편입 효과 본격화…3분기 연결기준 매출 48억원 기록
https://www.thebionews.net/news/articleView.html?idxno=28710
●SK바이오사이언스, 세포배양 독감 백신 ‘스카이셀플루’ 신규 광고 선봬
https://www.thebionews.net/news/articleView.html?idxno=28711
●디티앤씨알오, 비임상 분석 서비스 확대…TK 시료 활용 대사체 분석 지원
https://www.thebionews.net/news/articleView.html?idxno=28719
●디티앤씨알오, 신약 개발 전 주기 CRO 경쟁력 강화…산학·산업계 협력 확대
https://www.thebionews.net/news/articleView.html?idxno=28714
●GC녹십자, 국내외 학회서 독자 ‘mRNA-LNP 플랫폼’ 연구 성과 공개
https://www.thebionews.net/news/articleView.html?idxno=28701
●케이메디허브 “비욘드메디슨, ‘클릭리스’ 신의료기술평가 유예 대상 선정”
https://www.thebionews.net/news/articleView.html?idxno=28688
●[인사] 식품의약품안전처
https://www.thebionews.net/news/articleView.html?idxno=28720
●AstraZeneca’s ‘BREZTRI’ gains insurance coverage for COPD maintenance therapy – “Beyond symptom control to preventing exacerbations”
https://www.thebionews.net/news/articleView.html?idxno=28731
●AprilBio’s partner Evommune confirms significant therapeutic efficacy in Phase 2a for atopic dermatitis candidate
https://www.thebionews.net/news/articleView.html?idxno=28729
●Daewoong Pharmaceutical launches ‘Fexuclue’ in Indonesia, full-scale targeting KRW235 billion market
https://www.thebionews.net/news/articleView.html?idxno=28728
●Celltrion obtains U.S. Phase 3 clinical trial approval for ‘Zymfentra’ seeking expansion for rheumatoid arthritis indications
https://www.thebionews.net/news/articleView.html?idxno=28727
●LigaChem Biosciences completes IND preparation for next-generation BCMA-targeted ADC candidate ‘LCB43’
https://www.thebionews.net/news/articleView.html?idxno=28726
●European orphan drug designation nears for glioma treatment ‘RZ-001’
https://www.thebionews.net/news/articleView.html?idxno=28725
●G2GBIO expands global collaboration on long-acting injectables, partnership talks on track
https://www.thebionews.net/news/articleView.html?idxno=28724
●Vaxcellbio unveils two allogeneic CAR-NK studies at international NK cell conference ‘NK2026’
https://www.thebionews.net/news/articleView.html?idxno=28723
●‘BIX 2026’ Counts Down to Opening with Post-GLP-1 Session on the Next Obesity Treatment Market
https://www.thebionews.net/news/articleView.html?idxno=28693
*제약바이오 10월 2일 아침 유튜브 라디오 뉴스(매일 아침 업로드)
https://www.youtube.com/watch?v=STC7VUmj9qk